Table 2 Patients with isolated relapse in CNS group characteristics at the time of the first diagnosis
Pts | Age at Dx (y, m) | Gender | Stage at Dx | Primary site Metastases at diagnosis | MYCN amplification/ Type of pathology | Skull bones involvement at Dx | First line therapy |
|---|---|---|---|---|---|---|---|
1 | 2y 2Â m | F | 4 | Adrenal gland Bones, BM, LN | Yes UH | Yes | HR-NBL SIOPEN No anti-GD2 |
2 | 2y 2 m | M | 4 | Retroperitoneal space Bones, BM, LN | Yes UH | Yes – intracranial penetration | HR-NBL SIOPEN No anti-GD2 |
3 | 5Â m | F | 4 | Adrenal gland, Bones, BM, liver, kidneys, lungs, chest wall | Yes UH | No | HR-NBL SIOPEN No anti-GD2 |
4 | 3Â m | F | 4 | Adrenal gland Bones, BM, LN, lungs, liver, kidneys | Yes UH | No | HR-NBL SIOPEN With anti-GD2 |
5 | 2y 6Â m | F | 4 | Adrenal gland Bones, BM | Not evaluated UH | Yes | Conventional chemotherapy |
6 | 3y 7 m | F | 4 | Mediastinum Bones, BM, LN, CSN, pleura | No UH | Yes – CNS infiltration | HR-NBL SIOPEN with anti-GD2 |
7 | 2y 7Â m | M | 4 | Adrenal gland Bones, BM, LN | No UH | Yes | Conventional chemotherapy |
8 | 10Â m | M | 4 | Retroperitoneal space BM | Yes UH | No | HR-NBL SIOPEN No anti-GD2 |
9 | 11 m | M | 4 | Adrenal gland Bones, BM, LN | Yes UH | Yes – infiltration of skull base | HR-NBL SIOPEN With anti-GD2 |
10 | 2y 4Â m | F | 4 | Retroperitoneal space Bones, BM | No FH | Yes | HR-NBL SIOPEN No anti-GD2 |
11 | 1y 8Â m | M | 4 | Adrenal gland LN, mediastinum, bones, BM | Yes UH | Yes | HR-NBL SIOPEN With anti-GD2 |
12 | 1y 11 m | M | 4 | Adrenal gland LN, bones, BM | Yes UH | Yes – penetrating to CNS | HR-NBL SIOPEN With anti-GD2 |
13 | 6y 1m2 | M | 4 | Retroperitoneal space Bones, BM | No UH | No | HR-NBL SIOPEN With anti-GD2 |